News

Filter

Current filters:

Northwest Biotherapeutics

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

17-09-2014

The UK’s Department of Health announced that DCVax-L, the dendritic cell-based vaccine from US company…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyRegulationUK

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

12-06-2014

The glioblastoma multiforme (GBM) treatment market is forecast to expand rapidly from a value of $301…

Celldex TherapeuticsCotaraDCVaxMarkets & MarketingNorthwest BiotherapeuticsOncologyPeregrine PharmaceuticalsPharmaceuticalResearchrindopepimut

Rapid growth forecast for glioblastoma multiforme therapeutics market

Rapid growth forecast for glioblastoma multiforme therapeutics market

06-06-2014

According to a new report, growth in the glioblastoma multiforme (GBM) therapeutics market in major developed…

Celldex TherapeuticsCotaraMarkets & MarketingNorthwest BiotherapeuticsPeregrine PharmaceuticalsPharmaceuticalrindopepimut

NW Bio to expand manufacturing of DCVax products

27-01-2014

US biotech firm Northwest Biotherapeutics has entered into a set of agreements for large-scale expansion…

BiotechnologyDCVaxEuropeNorth AmericaNorthwest BiotherapeuticsProductionRegulationUSA

NWBT highlights cost effectiveness of DCVax in view of recent immunotherapy pricing concerns

11-08-2011

Northwest Biotherapeutics (OTCBB: NWBO.ob) yesterday reminded markets, in response to recent investor…

BiotechnologyDCVaxDendreonNorth AmericaNorthwest BiotherapeuticsOncologyPharmaceuticalPricingProvengeResearch

"Cancer vaccine revolution" seeing most striking data from Northwest Biotherapeutics, says analyst

29-06-2010

Pharmaceuticals and biotechnology analyst Navid Malik of the London-based Matrix Group, as part of an…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyPharmaceuticalResearchVaccines

Several parties interested in Northwest Biotherapeutics' immunotherapy cancer vaccines

17-06-2010

Last week, a detailed report authored by research pharmaceutical analyst Navid Malik caused some excitement…

DCVaxDendreonLicensingNorthwest BiotherapeuticsOncologyPharmaceuticalProvengeResearchVaccines

Back to top